What the First Year After a Hypoglossal Nerve Stimulation Implant Actually Involves

What Hypoglossal Nerve Stimulation Recovery Really Involves

Hypoglossal nerve stimulation recovery is a twelve-month process, not a two-week one. The operation is the short part. What follows is healing with no therapy at all, an activation visit, several programming visits, and one sleep study that fixes your final settings. If you are still deciding, our guide to who qualifies for airway stimulation and what it costs covers the step before this one.

Upper airway stimulation (UAS) treats obstructive sleep apnoea from the inside. A surgeon places a small stimulation lead cuff around a branch of the hypoglossal nerve, cranial nerve XII, which controls the tongue. A gentle pulse makes the genioglossus and geniohyoid muscles contract, pushing the tongue base forward so the airway stays open. In the most widely implanted design, an implantable pulse generator (IPG) sits below the collarbone and a pressure sensing lead reads your chest movement, so stimulation is respiration-synchronised and fires only as you inhale. Almost everyone who reaches this point arrives through CPAP intolerance or a failed mandibular advancement device, so it is late-line therapy.

Those outcomes are real. In a Belgian cohort of 39 implanted patients published in Life (Basel) in 2024, median apnoea-hypopnoea index (AHI) fell from 33.8 at baseline to 10.2 at six months and 9.6 at twelve. Surgical success by the Sher criteria was 80% at six months and 76% at twelve, median therapy use reached 7.0 hours a night, 94% used it more than four hours nightly, and every respondent preferred it to CPAP.

Weeks 0 to 6, Healing With No Therapy at All

The first six weeks are the part no clinic page describes honestly: your apnoea is untreated. The device is implanted but switched off while tissue heals around the stimulation lead cuff and the leads, and most teams will not activate it for four to six weeks. Some German centres quote six to eight. Someone who arrived with an AHI in the thirties spends that window with nothing.

Surgery takes around two hours. In many countries it is day surgery with same-day discharge; in Germany it is a standard inpatient (stationär) admission funded through the DRG system. Expect a chest X-ray before discharge to rule out pneumothorax risk where a chest pocket and tunnelled leads are used, a few days of pain relief, and about a week of antibiotics.

Early wound problems are usually minor: seroma, haematoma and device-site infection. Most centres restrict raising the arm on the implanted side for several weeks so the lead cannot migrate. Speech can be mildly slurred at first and swallowing can feel tight.

Month One, The Device Activation Appointment

Activation is a 30 to 45 minute outpatient visit, usually about four weeks after implantation. The clinician holds a programmer over the generator, wakes the device and raises the output while watching your tongue. Two thresholds are recorded. The sensory threshold is where you first feel the pulse. The functional threshold is where the tongue visibly moves correctly, meaning tongue protrusion forward rather than retraction.

You then receive a remote control: a start delay so you fall asleep before stimulation begins, a pause button for night-time awakenings, and a stop for the morning. Teams ask for nightly use from here, even while it is uncomfortable, because the implant's usage data drives the next appointments. The safety rule is not to raise your own amplitude by more than one level per week.

Most people tolerate their first settings reasonably well. A meaningful minority do not, and this is where sleep can get worse before it gets better, with awakenings from the stimulation sensation, tongue soreness and dry mouth.

Months Two to Twelve, Inside a Titration Appointment

The titration phase is where the year is really spent, and most pages summarise it as "the device is adjusted". Here is what is physically done. A 2025 case report in Frontiers in Medicine documents standard titration as taking 12 to 17 weeks after activation, with the wider published post-activation pathway running 3 to 12 months, a duration the authors describe as a source of patient frustration and dissatisfaction.

The Sleep Study That Sets Your Final Settings

Around three months after activation most teams order a sleep study, and which one you get matters. A home sleep apnoea test (HSAT) checks whether your current settings work during a normal night at home. An in-lab titration polysomnography is different: you sleep in a laboratory while a technician watches your airflow and remotely raises stimulation until obstruction clears. That night is the gate to your final settings.

The study reports the measures your team tracks for years: AHI, oxygen desaturation index (ODI) and time at therapeutic settings. Alongside it you repeat the Epworth Sleepiness Scale (ESS) for daytime sleepiness and the Functional Outcomes of Sleep Questionnaire (FOSQ) for how much apnoea limits daily life. In the five-year STAR trial results published by Woodson and colleagues in Otolaryngology–Head and Neck Surgery in 2018, the response rate, defined as an AHI under 20 with at least a 50% reduction, was 75% among 71 patients studied by polysomnography, falling to 63% under a more conservative analysis. ESS normalisation rose from 33% to 78%, FOSQ normalisation from 15% to 67%, and serious device-related adverse events, all involving lead or device adjustment, occurred in 6%.

The Adherence Curve Nobody Puts on a Clinic Page

Use falls during the first year while the stimulation needed rises. This is the most useful thing to know before consenting. Lenze and colleagues, in Sleep & Breathing (2025), followed 59 patients and found adherence, defined as at least four hours on at least 70% of nights, dropping from 79.7% at 0 to 3 months, to 59.3% at 3 to 6 months, to 52.5% at 6 to 9 months. Over the same period mean stimulation voltage climbed from 1.45 V at activation to 1.98 V at nine months, average nightly use fell from 425 to 362 minutes, and therapy pauses per night rose from 0.52 to 0.96, all statistically significant.

Read that curve as a warning, not a verdict. The Belgian twelve-month cohort reached 7.0 hours a night with 94% above the four-hour threshold, so a good year is achievable. What separates the two pictures is largely how actively the settings were managed. If your voltage is climbing and your pauses are increasing, request an earlier appointment.

Side Effects, MRI Limits and Daily Life

Most side effects are mechanical rather than dangerous: tongue soreness, tongue abrasion against the lower teeth, tingling, dry mouth from increased mouth breathing, mild difficulty swallowing, and temporary speech slurring early on. Tongue weakness is uncommon and usually settles. Lead migration, revision surgery and explantation sit at the serious end.

Imaging is the restriction people discover too late. The chest-generator system used across Europe is labelled MRI conditional at 1.5 T only, and scanning of the right upper chest and right upper arm is excluded, which matters if you may later need oncological or orthopaedic imaging. In a 2023 explantation case series in ORL, five patients were explanted 8 to 63 months after implantation, and the recorded reasons overlapped: two cases of intolerance of optimal stimulation settings, two of residual apnoea and two driven by a needed MRI, with a mean operative time of 162 minutes. Carry your device card, and tell any dentist, radiographer or surgeon first.

If the Implant Does Not Work For You

Roughly one implanted patient in four does not reach the surgical success threshold. The Belgian cohort reported 76% success at twelve months and the five-year trial data a 75% response rate, so a real minority finishes year one without the result they consented for.

The usual salvage step is a repeat drug-induced sleep endoscopy (DISE) performed with the stimulator running, so the surgeon can watch where the airway still collapses while the tongue is being stimulated. That map is then used to re-programme electrode configuration and amplitude, or to add a second treatment at another level of the airway. Explantation exists, but as a last resort.

If you screen out before surgery

Not everyone assessed reaches theatre. Complete concentric collapse (CCC) of the soft palate is a formal exclusion, and a 1,761-case DISE analysis in Sleep and Breathing (2024) found it in 22.3% of consecutive cases. Others fall outside the BMI cut-off of 32 kg/m², or sit below the AHI band the pathway covers. Then the conversation moves back to positional therapy, weight management, a mandibular advancement device, or, for snoring and mild-to-moderate obstructive apnoea, a soft silicone intranasal stent such as Back2Sleep, a CE-certified Class I device that needs no prescription and no electricity. Our ranking of evidence-based options when CPAP fails shows how these compare.

Why Hypoglossal Nerve Stimulation Recovery Starts Differently in Europe

Your year one begins when a centre can implant you, and in Europe that is a rationing question before it is a clinical one. In France, stimulation du nerf hypoglosse has been reimbursed since September 2024, capped at 400 devices per year at roughly €20,000 each, across fewer than ten implanting centres in 2025. The 2026 SFRMS, SPLF and SFORL joint position paper sets eligibility as adults with BMI under 32 kg/m², AHI between 15 and 50 per hour, fewer than 25% central events, and failure or contraindication of PPC and/or an orthèse d'avancée mandibulaire (OAM). It is positioned explicitly as third-line therapy for SAHOS, and the same paper reports 93% Sher-criteria success at twelve months, with 82% reaching an AHI below 15.

Germany funds implantation through the DRG system, with no prior insurer authorisation before the first clinic visit. In the United Kingdom, NICE guidance IPG598 is now HealthTech guidance HTG455; NICE judged the evidence limited in quantity and quality and restricted the procedure to special arrangements for governance, consent and audit, with access through NHS specialised commissioning. Europe also offers a second device architecture.

That architecture removes the chest wound, the arm restriction, the pneumothorax risk and the eventual battery surgery, and adds a small external part to wear and charge nightly. Other stimulation designs are in development, and our overview of the next generation of stimulation implants reaching Europe tracks where each stands. European outcome data exists too: the international ADHERE registry enrols across more than 50 centres including Belgian, German, Swiss and Dutch sites, so ask your surgeon for cohorts implanted under your own national pathway.

Frequently Asked Questions